AU2013229008B2 - Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof - Google Patents
Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof Download PDFInfo
- Publication number
- AU2013229008B2 AU2013229008B2 AU2013229008A AU2013229008A AU2013229008B2 AU 2013229008 B2 AU2013229008 B2 AU 2013229008B2 AU 2013229008 A AU2013229008 A AU 2013229008A AU 2013229008 A AU2013229008 A AU 2013229008A AU 2013229008 B2 AU2013229008 B2 AU 2013229008B2
- Authority
- AU
- Australia
- Prior art keywords
- cells
- fasl
- mar
- hours
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 83
- 230000006882 induction of apoptosis Effects 0.000 title description 22
- 210000004027 cell Anatomy 0.000 claims abstract description 320
- 230000006907 apoptotic process Effects 0.000 claims abstract description 134
- 102000005962 receptors Human genes 0.000 claims abstract description 34
- 108020003175 receptors Proteins 0.000 claims abstract description 34
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 147
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims description 147
- 239000003446 ligand Substances 0.000 claims description 102
- 210000000130 stem cell Anatomy 0.000 claims description 85
- 210000004988 splenocyte Anatomy 0.000 claims description 79
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 71
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 61
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 57
- 230000001939 inductive effect Effects 0.000 claims description 52
- 238000002054 transplantation Methods 0.000 claims description 43
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 42
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 42
- 101150064015 FAS gene Proteins 0.000 claims description 33
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 32
- 230000000735 allogeneic effect Effects 0.000 claims description 30
- 230000014509 gene expression Effects 0.000 claims description 29
- 210000001185 bone marrow Anatomy 0.000 claims description 23
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 16
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 14
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 14
- 239000000560 biocompatible material Substances 0.000 claims description 9
- 102000015212 Fas Ligand Protein Human genes 0.000 claims description 8
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 8
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 7
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 7
- 229920000609 methyl cellulose Polymers 0.000 claims description 5
- 239000001923 methylcellulose Substances 0.000 claims description 5
- 210000000952 spleen Anatomy 0.000 claims description 5
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 4
- 230000001976 improved effect Effects 0.000 claims description 4
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 4
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 abstract description 91
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract description 78
- 230000001404 mediated effect Effects 0.000 abstract description 36
- 210000002865 immune cell Anatomy 0.000 abstract description 23
- 238000011534 incubation Methods 0.000 description 73
- 210000004700 fetal blood Anatomy 0.000 description 65
- 239000002609 medium Substances 0.000 description 61
- 108090000623 proteins and genes Proteins 0.000 description 59
- 102000004169 proteins and genes Human genes 0.000 description 52
- 210000004698 lymphocyte Anatomy 0.000 description 45
- 230000000694 effects Effects 0.000 description 41
- 230000034994 death Effects 0.000 description 36
- 241000699670 Mus sp. Species 0.000 description 34
- 238000001802 infusion Methods 0.000 description 26
- 206010028980 Neoplasm Diseases 0.000 description 25
- 230000003394 haemopoietic effect Effects 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- 210000005259 peripheral blood Anatomy 0.000 description 20
- 239000011886 peripheral blood Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 230000006786 activation induced cell death Effects 0.000 description 19
- 238000011579 SCID mouse model Methods 0.000 description 18
- 239000000427 antigen Substances 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 230000001640 apoptogenic effect Effects 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 16
- 206010068051 Chimerism Diseases 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 210000003719 b-lymphocyte Anatomy 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000008030 elimination Effects 0.000 description 14
- 238000003379 elimination reaction Methods 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 231100000518 lethal Toxicity 0.000 description 14
- 230000001665 lethal effect Effects 0.000 description 14
- 108091033319 polynucleotide Proteins 0.000 description 14
- 102000040430 polynucleotide Human genes 0.000 description 14
- 239000002157 polynucleotide Substances 0.000 description 14
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 13
- 230000004913 activation Effects 0.000 description 12
- 210000000066 myeloid cell Anatomy 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 230000003211 malignant effect Effects 0.000 description 11
- 230000002265 prevention Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 238000011533 pre-incubation Methods 0.000 description 10
- 230000004580 weight loss Effects 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- 206010070834 Sensitisation Diseases 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 210000002798 bone marrow cell Anatomy 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 108010052621 fas Receptor Proteins 0.000 description 8
- 102000018823 fas Receptor Human genes 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 230000008313 sensitization Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 102000009058 Death Domain Receptors Human genes 0.000 description 6
- 108010049207 Death Domain Receptors Proteins 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000003827 upregulation Effects 0.000 description 6
- 108090000672 Annexin A5 Proteins 0.000 description 5
- 102000004121 Annexin A5 Human genes 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 108700012920 TNF Proteins 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000003750 conditioning effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000005087 mononuclear cell Anatomy 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- -1 polypropylene Polymers 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 229920001917 Ficoll Polymers 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 102000000646 Interleukin-3 Human genes 0.000 description 4
- 108010002386 Interleukin-3 Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000001143 conditioned effect Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 229940076264 interleukin-3 Drugs 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000001400 myeloablative effect Effects 0.000 description 4
- 210000001178 neural stem cell Anatomy 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011127 radiochemotherapy Methods 0.000 description 4
- 230000004043 responsiveness Effects 0.000 description 4
- 238000010187 selection method Methods 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 108700005078 Synthetic Genes Proteins 0.000 description 3
- 108700012411 TNFSF10 Proteins 0.000 description 3
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 3
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000000961 alloantigen Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000018486 cell cycle phase Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000011124 ex vivo culture Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000002825 functional assay Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000000861 pro-apoptotic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 206010021450 Immunodeficiency congenital Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 230000005756 apoptotic signaling Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000003021 clonogenic effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 102000057041 human TNF Human genes 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000016245 inborn errors of metabolism Diseases 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000441 neoplastic stem cell Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
- 230000002629 repopulating effect Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 238000007801 sublethal irradiation Methods 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 208000016216 Choristoma Diseases 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102000010969 Cytokine TWEAK Human genes 0.000 description 1
- 108010037645 Cytokine TWEAK Proteins 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 1
- 102000017095 Leukocyte Common Antigens Human genes 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100369993 Mus musculus Tnfsf10 gene Proteins 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710123874 Protein-glutamine gamma-glutamyltransferase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000193448 Ruminiclostridium thermocellum Species 0.000 description 1
- 102000012010 Sialomucins Human genes 0.000 description 1
- 108010061228 Sialomucins Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000000649 b-lymphocyte subset Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004703 blastocyst inner cell mass Anatomy 0.000 description 1
- 238000011094 buffer selection Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000009643 clonogenic assay Methods 0.000 description 1
- 231100000096 clonogenic assay Toxicity 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000010228 ex vivo assay Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 208000017830 lymphoblastoma Diseases 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical compound NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607033P | 2012-03-06 | 2012-03-06 | |
| US61/607033 | 2012-03-06 | ||
| PCT/IL2013/000026 WO2013132477A1 (en) | 2012-03-06 | 2013-03-05 | Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013229008A1 AU2013229008A1 (en) | 2014-09-18 |
| AU2013229008B2 true AU2013229008B2 (en) | 2018-11-08 |
Family
ID=49116028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013229008A Ceased AU2013229008B2 (en) | 2012-03-06 | 2013-03-05 | Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9783778B2 (https=) |
| EP (2) | EP2823040B1 (https=) |
| JP (1) | JP6429191B2 (https=) |
| KR (1) | KR101912982B1 (https=) |
| CN (2) | CN109116033A (https=) |
| AU (1) | AU2013229008B2 (https=) |
| CA (1) | CA2866358C (https=) |
| DK (1) | DK2823040T3 (https=) |
| IL (1) | IL234459B (https=) |
| RU (1) | RU2630301C2 (https=) |
| WO (1) | WO2013132477A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3054961B1 (en) * | 2013-10-09 | 2020-08-26 | Cellect Biotherapeutics Ltd. | Activation of hematopoietic progenitors by pretransplant exposure to death ligands |
| WO2016193986A2 (en) | 2015-06-05 | 2016-12-08 | Cellect Biotherapeutics Ltd. | Selective surfaces for, and methods of, selecting a population of stem and progenitor cells, and uses thereof |
| EP3841196A4 (en) * | 2018-08-22 | 2022-09-21 | Cellect Biotherapeutics Ltd. | MODULATION OF CELLS RESPONSIVE TO APOPTOSIS |
| US20220002363A1 (en) * | 2020-07-03 | 2022-01-06 | United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods for treating pulmonary disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007138597A2 (en) * | 2006-05-31 | 2007-12-06 | Styx Llc | Methods of selecting stem cells and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| JPS61235752A (ja) | 1985-04-11 | 1986-10-21 | Asahi Optical Co Ltd | 細胞分離材、分離器および分離方法 |
| IT8523298V0 (it) * | 1985-10-02 | 1985-10-02 | Pierrel Hospital Spa | Catetere venoso centrale. |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US4979959A (en) | 1986-10-17 | 1990-12-25 | Bio-Metric Systems, Inc. | Biocompatible coating for solid surfaces |
| US4885234A (en) | 1988-09-29 | 1989-12-05 | Eastman Kodak Company | Photographic materials containing stable cyan coupler formulations |
| US5998024A (en) | 1995-02-02 | 1999-12-07 | Rainer H. Frey | Biocompatible material and method of manufacture and use thereof |
| HUP0003349A3 (en) | 1997-05-14 | 2001-12-28 | Aventis Pharmaceuticals Inc Co | Peptide parathyroid hormone analogs, pharmaceutical compositions comprising thereof and their use |
| US6040182A (en) | 1997-11-12 | 2000-03-21 | Becton Dickinson And Company | Method and materials for efficiency protein immobilization on tissue culture treated assay plates |
| GB9724270D0 (en) | 1997-11-17 | 1998-01-14 | Babraham The Inst | Methods and means for mutagenesis of dna |
| DE69900984T2 (de) | 1998-04-22 | 2002-10-31 | St. Jude Medical Ab, Jaerfaella | Biokompatibles material für implantate |
| US20010049115A1 (en) * | 2000-01-17 | 2001-12-06 | Collins John Kevin | Vitro model for gastrointestinal inflammation |
| US20090130718A1 (en) | 1999-02-04 | 2009-05-21 | Diversa Corporation | Gene site saturation mutagenesis |
| US20030119185A1 (en) * | 2000-02-24 | 2003-06-26 | Xcyte Therapies, Inc. | Activation and expansion of cells |
| WO2003002761A1 (en) | 2001-06-29 | 2003-01-09 | Novozymes A/S | Method of multimerization and site-directed mutagenesis |
| JP2005514617A (ja) * | 2001-07-02 | 2005-05-19 | ザ、ボード、オブ、トラスティーズ、オブ、ザ、リーランド、スタンフォード、ジュニア、ユニバーシティ | 細胞の表現型決定および操作のためのマイクロアレイ |
| EP1281767A3 (en) | 2001-07-31 | 2003-05-28 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of tumors |
| DE10144252A1 (de) * | 2001-08-31 | 2003-03-27 | Fraunhofer Ges Forschung | Nanopartikel mit daran immobilisiertem biologisch aktivem TNF |
| WO2003106692A2 (en) * | 2002-06-13 | 2003-12-24 | Merck Patent Gmbh | Methods for the identification of all-antigens and their use for cancer therapy and transplantation |
| DE60334474D1 (de) * | 2002-07-12 | 2010-11-18 | Univ Johns Hopkins | Reagenzien und verfahren zum eingriff in einzigartige klonotype lymphozyten-rezeptoren |
| US20060009623A1 (en) | 2004-07-06 | 2006-01-12 | National University Of Singapore | C-terminal attachment of ligands to proteins for immobilization onto a support |
| AU2005291298B2 (en) * | 2004-10-01 | 2012-01-19 | Apoxis Sa | Method for ex-vivo purging in autologous transplantation |
| ZA200704252B (en) * | 2004-10-25 | 2009-09-30 | Cellerant Therapeutics Inc | Methods of expanding myeloid cell populations and uses thereof |
| DE602005008265D1 (de) * | 2005-12-23 | 2008-08-28 | Biedermann Motech Gmbh | Flexible Stabilisierungsvorrichtung zur dynamischen Stabilisierung von Knochen oder Wirbeln |
| CN101517070A (zh) * | 2006-05-31 | 2009-08-26 | Styx有限责任公司 | 选择干细胞的方法及其用途 |
| CN101711360A (zh) * | 2007-03-16 | 2010-05-19 | 赛乐思迪斯有限公司 | 细胞介导的免疫应答检验及其试剂盒 |
| KR100920729B1 (ko) | 2007-10-01 | 2009-10-07 | 한국생명공학연구원 | 펩타이드 혼성체를 사용한 배향성이 조절된 항체단분자막의 제조방법 |
| US20100040583A1 (en) | 2008-03-27 | 2010-02-18 | Vincent Falanga | Compositions and methods using stem cells in cutaneous wound healing |
| EP2274617A4 (en) * | 2008-04-10 | 2011-11-09 | Massachusetts Inst Technology | METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS |
| AU2009257230B2 (en) | 2008-06-13 | 2015-05-28 | Smith & Nephew, Inc. | Fixation devices for tissue repair |
| CN104357381A (zh) * | 2008-10-31 | 2015-02-18 | 辛西斯有限责任公司 | 用于活化干细胞的方法和装置 |
| GB0823553D0 (en) | 2008-12-24 | 2009-01-28 | Immunosolv Ltd | Cell separation technique |
| JP2010227313A (ja) * | 2009-03-27 | 2010-10-14 | Seiko Epson Corp | がん細胞除去システムおよびがん細胞除去装置 |
| JP5327457B2 (ja) * | 2009-03-27 | 2013-10-30 | セイコーエプソン株式会社 | がん細胞分離装置およびその製造方法 |
| WO2012011113A2 (en) * | 2010-07-22 | 2012-01-26 | Shai Yarkoni | Regulatory immune cells with enhanced targeted cell death effect |
-
2013
- 2013-03-05 CA CA2866358A patent/CA2866358C/en active Active
- 2013-03-05 CN CN201810972287.2A patent/CN109116033A/zh active Pending
- 2013-03-05 KR KR1020147027817A patent/KR101912982B1/ko not_active Expired - Fee Related
- 2013-03-05 RU RU2014138001A patent/RU2630301C2/ru active
- 2013-03-05 CN CN201380021092.5A patent/CN104245924B/zh not_active Expired - Fee Related
- 2013-03-05 US US14/383,288 patent/US9783778B2/en not_active Expired - Fee Related
- 2013-03-05 WO PCT/IL2013/000026 patent/WO2013132477A1/en not_active Ceased
- 2013-03-05 DK DK13758162.5T patent/DK2823040T3/en active
- 2013-03-05 EP EP13758162.5A patent/EP2823040B1/en active Active
- 2013-03-05 AU AU2013229008A patent/AU2013229008B2/en not_active Ceased
- 2013-03-05 EP EP18181773.5A patent/EP3486315A1/en not_active Withdrawn
- 2013-03-05 JP JP2014560516A patent/JP6429191B2/ja not_active Expired - Fee Related
-
2014
- 2014-09-04 IL IL234459A patent/IL234459B/en active IP Right Grant
-
2017
- 2017-09-07 US US15/697,928 patent/US20180208888A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007138597A2 (en) * | 2006-05-31 | 2007-12-06 | Styx Llc | Methods of selecting stem cells and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2866358A1 (en) | 2013-09-12 |
| EP3486315A1 (en) | 2019-05-22 |
| US9783778B2 (en) | 2017-10-10 |
| US20150044182A1 (en) | 2015-02-12 |
| JP6429191B2 (ja) | 2018-11-28 |
| EP2823040B1 (en) | 2018-08-01 |
| RU2014138001A (ru) | 2016-04-20 |
| WO2013132477A1 (en) | 2013-09-12 |
| JP2015510758A (ja) | 2015-04-13 |
| CN109116033A (zh) | 2019-01-01 |
| RU2630301C2 (ru) | 2017-09-06 |
| IL234459B (en) | 2020-02-27 |
| KR20150011796A (ko) | 2015-02-02 |
| EP2823040A1 (en) | 2015-01-14 |
| CN104245924A (zh) | 2014-12-24 |
| CA2866358C (en) | 2020-06-23 |
| KR101912982B1 (ko) | 2018-10-29 |
| US20180208888A1 (en) | 2018-07-26 |
| EP2823040A4 (en) | 2016-01-06 |
| AU2013229008A1 (en) | 2014-09-18 |
| CN104245924B (zh) | 2020-05-01 |
| DK2823040T3 (en) | 2018-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101518409B1 (ko) | 단핵세포 증량 방법 | |
| Boieri et al. | The role of animal models in the study of hematopoietic stem cell transplantation and GvHD: a historical overview | |
| Neagu¹ | The immune system-a hidden treasure for biomarker discovery in cutaneous melanoma | |
| CN104774261A (zh) | Foxm1肽和包含foxm1肽的药剂 | |
| US20180208888A1 (en) | Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof | |
| WO2007082177A2 (en) | Myeloid suppressor cells, methods for preparing them, and methods for using them for treating autoimmunity | |
| EP3303563B1 (en) | Selective surfaces for, and methods of, selecting a population of stem and progenitor cells, and uses thereof | |
| Zorina | New Insights on the Role of the Mesenchymal–Hematopoietic Stem Cell Axis in Autologous and Allogeneic Hematopoiesis | |
| CN113056555A (zh) | 凋亡易感细胞的调节 | |
| Pietrzyk et al. | Quantitative gene expression analysis of fractalkine using laser microdissection in biopsies from kidney allografts with acute rejection | |
| CN101031642B (zh) | 自体移植中离体净化的方法 | |
| Jones | The immunobiology of graft-versus-host disease across a minor histocompatibility antigen barrier | |
| Horwitz | Mesenchymal Stromal Cells and Hematopoietic Cell Transplantation | |
| Striz et al. | Interleukin 18 (IL-18) Upregulation in Acute Rejection of Kidney Allograft | |
| Zhou et al. | Endogenous C3 expression affects the potency of macrophages as stimulators of T cell alloreactivity | |
| Ushigome et al. | GITR activation in donor specific transfusion accelerates allograft rejection | |
| Wyburn et al. | MACROPHAGE-DERIVED INTERLEUKIN-18 IN ACUTE RAT RENAL ALLOGRAFT REJECTION. | |
| Rondelli et al. | DIFFERENT RECONSTITUTION OF CIRCULATING LYMPHOCYTES AND DENDRITIC CELLS AFTER ALLOGENEIC LIVER AND KIDNEY TRANSPLANTATION | |
| Costa et al. | ADOPTIVE TRANSFER OF ANTI-CD45RB TREATED LYMPHOCYTES PREVENTS DIABETES MELLITUS ONSET IN NOD MICE | |
| Singer et al. | Inhibition of T Cell Activation Through Interruption of Adaptor Protein Associations | |
| Azimzadeh et al. | MODULATION OF IMMUNE RESPONSES TO HEART ALLOGRAFTS BY DONOR BONE MARROW INFUSION IN MONKEYS TREATED WITH CD154 COSTIMULATION BLOCKADE | |
| Bentlejwesky et al. | KINETICS OF T CELL MEMORY RECOVERY IN LUNG TRANSPLANT RECIPIENTS TREATED WITH T CELL DEPLETION THERAPIES | |
| Lehle et al. | PREDOMINANT INHIBITON OF INTERLEUKIN-6 SYNTHESIS IN PATIENT SPECIFIC ENDOTHELIAL CELLS BY M-TOR INHIBITORS BELOW A CONCENTRATION RANGE WHERE CELL PROLIFERATION IS AFFECTED AND MITOTIC ARREST TAKES PLACE. | |
| Tokita et al. | LIVER SINUSOIDAL ENDOTHELIAL CELLS ENDOCYTOSED ALLOGENEIC CELLS TOLERIZE T CELL RECOGNIZING ALLO-ANTIGENS THROUGH INDIRECT RECOGNITION BY FAS-FAS LIGAND PATHWAY. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: CELLECT BIOTHERAPEUTICS LTD Free format text: FORMER NAME(S): CELLECT BIOTECHNOLOGY LTD |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |